Acute lymphoblastic leukaemia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 121
• CD22 33
• ABL1 10
• KMT2A 8
• CD20 8
• TP53 0
• AKT 0
• BCL-2 3
• PI3K 0
• CD123 5
• JAK 2
• CD38 4
• PD-1 3
• RUNX1 0
• mTOR 0
• NPM1 4
• BCMA 4
• NOTCH1 0
• CXCR4 1
• PTEN 0
• CTNNB1 0
• EGFR 0
• HDAC 0
• IDH 0
• MYC 0
• RAS 0
• STAT3 0
• AMPK 0
• CD30 0
• CD40 0
• CD47 0
• ERK 0
• FGFR 0
• MAPK 0
• MDM2 0
• PD-L1 0
• CD33 1
• FLT3 0
• IL-1 0
• IL-17 0
• IL-6 0
• KRAS 0
• MEK 0
• PPAR 0
• RANKL 0
• RB1 0
• TYK2 0
• ALK 0
• AXL 0
• BRCA1 0
• BRD4 0
• BTK 0
• CDK4/6 0
• CDKN2A 0
• CTLA-4 0
• EZH2 0
• FAK 0
• FTO 0
• GPRC5D 1
• GPX4 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 1,227 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  SPARK-ALL: Calaspargase Pegol in Adults With ALL

  NCT04817761· Institut de Recherches Internationales Servier· Updated 29 Oct 2026

  “Sponsor decision.”Registry text, quoted unchanged. Source

• Suspended

  Pyronaridine in Acute Myeloid Leukemia (AML)

  NCT05291390· Armaceutica, Inc.· Updated 19 Oct 2026

  “Change of protocol”Registry text, quoted unchanged. Source

• Terminated

  Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"

  NCT04920968· Maria Sklodowska-Curie National Research Institute of Oncology· Updated 15 Oct 2026

  “Following the recommendation of the Data Monitoring Committee (DMC), based on the results of the interim analysis, the Sponsor has decided to terminate the study prematurely”Registry text, quoted unchanged. Source

• Withdrawn

  Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

  NCT05410041· Beijing Boren Hospital· Updated 15 Oct 2026

  “No participants.”Registry text, quoted unchanged. Source

• Suspended

  Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

  NCT06195891· City of Hope Medical Center· Updated 15 Oct 2026

  “Timeline Adjustment”Registry text, quoted unchanged. Source

• Suspended

  Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia

  NCT07192237· M.D. Anderson Cancer Center· Updated 8 Oct 2026

  “PI requested”Registry text, quoted unchanged. Source

• Suspended

  A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home

  NCT06639958· Children's Oncology Group· Updated 5 Oct 2026

  “All potential pilot phase pts have been enrolled.”Registry text, quoted unchanged. Source

• Terminated

  Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase

  NCT07320534· Gadjah Mada University· Updated 1 Oct 2026

  “Interim analysis showed no significant benefit of levofloxacin. Prolonged antibiotic use may increase adverse effects and resistance. Limited funding and the approaching end of the study period also supported early termination.”Registry text, quoted unchanged. Source

• Suspended

  Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

  NCT06738368· University of Washington· Updated 29 Sept 2026

  “Safety Review”Registry text, quoted unchanged. Source

• Suspended

  Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

  NCT03494569· City of Hope Medical Center· Updated 28 Sept 2026

  “Accrual goal”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

  NCT05621291· National Cancer Institute (NCI)· Source

• Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT07572136· National Cancer Institute (NCI)· Source

• Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

  NCT04512716· Memorial Sloan Kettering Cancer Center· Source

• Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

  NCT04703192· Daiichi Sankyo· Source

• BLinatumomab and iNKT in Relapsed B-Cell ALL

  NCT07869368· UNC Lineberger Comprehensive Cancer Center· Source

• A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

  NCT07223021· Memorial Sloan Kettering Cancer Center· Source

• Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  NCT02390752· National Cancer Institute (NCI)· Source

• Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

  NCT06054113· Amgen· Source

• A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  NCT03914625· National Cancer Institute (NCI)· Source

• Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

  NCT06904066· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 4
• CRISPR-Cas Systems 5
• Gene Expression Profiling 27
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 4
• Flow Cytometry 40
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 50
• Magnetic Resonance Imaging 14
• Machine Learning 11
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 8

• An Artificial Intelligence Framework for Detection of Leukemia with Comparison Between Segmented and Non-Segmented Images.

  Sensors (Basel), Oct 2026

• ClinNetDx: a novel explainable ai framework for acute lymphoblastic leukemia detection using multi-modal clinical data.

  BMC Cancer, Jul 2026

• Detection of acute lymphocytic and myeloid leukaemia with optimized dimensionality reduction and deep learning classification framework.

  Curr Res Transl Med, Jun 2026

• An explainable meta-learned hybrid CNN-transformer model with dual attention for leukemia diagnosis from peripheral blood smears.

  Sci Rep, Jun 2026

• A systematic review of machine and deep learning techniques for acute lymphoblastic leukemia diagnosis.

  Artif Intell Med, Mar 2026

• Improving acute lymphoblastic leukemia diagnosis through CBAM-enhanced VGG19 deep learning.

  Sci Rep, Feb 2026

• Reliable leukemia detection via transfer-enhanced Bayesian CNNs.

  Comput Biol Med, Jan 2026

• Blast cell segmentation and leukemia classification using hybrid Deep Kronecker WideResNet using blood smear images.

  Comput Biol Chem, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.